These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8462390)

  • 1. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
    Nagi DK; Yudkin JS
    Diabetes Care; 1993 Apr; 16(4):621-9. PubMed ID: 8462390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
    Grant PJ
    Diabetes Care; 1996 Jan; 19(1):64-6. PubMed ID: 8720537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
    Fontbonne A; Charles MA; Juhan-Vague I; Bard JM; André P; Isnard F; Cohen JM; Grandmottet P; Vague P; Safar ME; Eschwège E
    Diabetes Care; 1996 Sep; 19(9):920-6. PubMed ID: 8875083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.
    Chan JC; Tomlinson B; Critchley JA; Cockram CS; Walden RJ
    Diabetes Care; 1993 Jul; 16(7):1035-8. PubMed ID: 8359098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
    Brussaard HE; Gevers Leuven JA; Frölich M; Kluft C; Krans HM
    Diabetologia; 1997 Jul; 40(7):843-9. PubMed ID: 9243107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
    Goldstein BJ; Weissman PN; Wooddell MJ; Waterhouse BR; Cobitz AR
    Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study.
    Haffner SM; D'Agostino R; Mykkänen L; Tracy R; Howard B; Rewers M; Selby J; Savage PJ; Saad MF
    Diabetes Care; 1999 Apr; 22(4):562-8. PubMed ID: 10189532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis and diabetic retinopathy in NIDDM.
    Mansfield MW; Grant PJ
    Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control.
    Willey KA; Molyneaux LM; Yue DK
    Diabet Med; 1994; 11(7):701-4. PubMed ID: 7955998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors.
    Landin K; Tengborn L; Smith U
    J Intern Med; 1991 Feb; 229(2):181-7. PubMed ID: 1900072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
    Palumbo PJ
    J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
    Hermann LS; Ranstam J; Vaaler S; Melander A
    Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk factor profile 5 years after diagnosis of NIDDM.
    Gottsäter A; Ahmed M; Lilja B; Fernlund P; Sundkvist G
    Diabetes Care; 1996 Jan; 19(1):60-3. PubMed ID: 8720536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.